专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US6110968A Methods for treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts 失效
标题翻译：治疗方法是基于烟草及其燃烧副产物中先进的糖基化终产物的存在
公开(公告)号：US6110968A
公开(公告)日：2000-08-29
申请号：US189191
申请日：1998-11-10
申请人： Richard J. Bucala , Helen Vlassara , Anthony Cerami , Carla J. Cerami , Henry W. Founds
发明人： Richard J. Bucala , Helen Vlassara , Anthony Cerami , Carla J. Cerami , Henry W. Founds
IPC分类号： A24B15/36 , A24D3/14 , A61K31/27 , A61K31/275
CPC分类号： G01N33/6842 , A24B15/36 , A24B15/365 , A24D3/14
摘要： Methods are provided for measuring the accumulation of advanced glycosylation endproducts (AGEs), and for lowering the accumulation of advanced glycosylation endproducts, which are predicated on the discovery that such AGEs and their precedent glycotoxins are present in tobacco and its byproducts. More particularly, the methods focus on the observation that individuals who smoke or otherwise use tobacco have increased levels of AGEs relative to non-smoking individuals. The present methods relate to the measurement of AGE levels in both individuals and in tobacco and its byproduct, smoke, and to the treatment of such individuals with agents capable of reacting with glycosylation products to either avert or diminish the accretion of AGEs in the body. Methods are also provided for the evaluation of the tobacco products to determine their storage status and organoleptic capacity and potential, for the treatment of the ambient atmosphere to lower AGE levels, and for the treatment of the tobacco products and combustion byproducts to lower AGE levels therein. For example, air or other samples may be taken and evaluated by a dosimeter or like device, to determine whether AGE levels exceed normal, after which measures could be implemented to remediate the ambient condition. Likewise, filters and similar devices for removing AGEs from tobacco smoke are provided. All such methods and corresponding materials are contemplated and included.
摘要翻译：提供了用于测量晚期糖基化终产物（AGEs）的积累以及用于降低晚期糖基化终产物的积累的方法，其基于发现这样的AGEs及其先例的糖类毒素存在于烟草及其副产物中。更具体地说，这些方法着重于观察吸烟或以其他方式使用烟草的个体相对于非吸烟者的AGEs水平的增加。本方法涉及测量个体和烟草及其副产物，烟雾中的AGE水平，以及能够与糖基化产物反应的试剂对这些个体的治疗，以反转或减少AGEs在体内的积累。还提供了用于评价烟草制品以确定其储存状态和感官能力和潜力的方法，用于处理环境大气以降低AGE水平，以及用于处理烟草制品和燃烧副产物以降低其AGE水平。例如，空气或其他样品可以通过剂量计或类似装置进行评估，以确定AGE水平是否超过正常，之后可以实施措施来修复环境条件。同样，提供了用于从AGE烟草烟雾中除去的过滤器和类似装置。所有这些方法和相应的材料都被考虑并包括在内。

2. 发明授权

US5850840A Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts 失效
标题翻译：基于烟草及其燃烧副产物中高级糖基化终产物的存在的测量和处理方法
公开(公告)号：US5850840A
公开(公告)日：1998-12-22
申请号：US772335
申请日：1996-12-23
申请人： Carla J. Cerami , Richard J. Bucala , Helen Vlassara , Anthony Cerami , Henry W. Founds
发明人： Carla J. Cerami , Richard J. Bucala , Helen Vlassara , Anthony Cerami , Henry W. Founds
IPC分类号： A24B15/36 , A24D3/14 , A24D3/16 , A24F1/10
CPC分类号： G01N33/6842 , A24B15/36 , A24B15/365 , A24D3/14 , A24D3/16
摘要： Methods are provided for measuring the accumulation of advanced glycosylation endproducts (AGEs), and for lowering the accumulation of advanced glycosylation endproducts, which are predicated on the discovery that such AGEs and their precedent glycotoxins are present in tobacco and its byproducts. More particularly, the methods focus on the observation that individuals who smoke or otherwise use tobacco have increased levels of AGEs relative to non-smoking individuals. The present methods relate to the measurement of AGE levels in both individuals and in tobacco and its byproduct, smoke, and to the treatment of such individuals with agents capable of reacting with glycosylation products to either avert or diminish the accretion of AGEs in the body. Methods are also provided for the evaluation of the tobacco products to determine their storage status and organoleptic capacity and potential, for the treatment of the ambient atmosphere to lower AGE levels, and for the treatment of the tobacco products and combustion byproducts to lower AGE levels therein. For example, air or other samples may be taken and evaluated by a dosimeter or like device, to determine whether AGE levels exceed normal, after which measures could be implemented to remediate the ambient condition. Likewise, filters and similar devices for removing AGEs from tobacco smoke are provided. All such methods and corresponding materials are contemplated and included.
摘要翻译：提供了用于测量晚期糖基化终产物（AGEs）的积累以及用于降低晚期糖基化终产物的积累的方法，其基于发现这样的AGEs及其先例的糖类毒素存在于烟草及其副产物中。更具体地说，这些方法着重于观察吸烟或以其他方式使用烟草的个体相对于非吸烟者的AGEs水平的增加。本方法涉及测量个体和烟草及其副产物，烟雾中的AGE水平，以及能够与糖基化产物反应的试剂对这些个体的治疗，以反转或减少AGEs在体内的积累。还提供了用于评价烟草制品以确定其储存状态和感官能力和潜力的方法，用于处理环境大气以降低AGE水平，以及用于处理烟草制品和燃烧副产物以降低其AGE水平。例如，空气或其他样品可以通过剂量计或类似装置进行评估，以确定AGE水平是否超过正常，之后可以实施措施来修复环境条件。同样，提供了用于从AGE烟草烟雾中除去的过滤器和类似装置。所有这些方法和相应的材料都被考虑并包括在内。

3. 发明授权

US5854000A Methods for measurement predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts 失效
标题翻译：测定方法是基于烟草及其燃烧副产物中先进的糖基化终产物的存在
公开(公告)号：US5854000A
公开(公告)日：1998-12-29
申请号：US617349
申请日：1996-03-18
申请人： Richard J. Bucala , Helen Vlassara , Anthony Cerami , Henry W. Founds
发明人： Richard J. Bucala , Helen Vlassara , Anthony Cerami , Henry W. Founds
IPC分类号： A24B15/36 , A24D3/14 , A24D3/16 , G01N33/53 , G01N30/02 , G01N30/90 , G01N33/537 , G01N33/542 , G01N33/543 , G01N33/551 , G01N33/566
CPC分类号： G01N33/6842 , A24B15/36 , A24B15/365 , A24D3/14 , A24D3/16 , Y10S436/803 , Y10S436/815 , Y10S436/90 , Y10S436/901
摘要： Methods are disclosed for measuring the accumulation of advanced glycosylation endproducts (AGEs), which are predicated on the discovery that such AGEs are present in tobacco and its byproducts. More particularly, the methods focus on the observation that individuals who smoke or otherwise use tobacco have increased levels of AGEs over non-smoking individuals. The present methods relate to the measurement of AGE levels in both individuals and in tobacco and its byproduct, smoke. Methods are also disclosed for the evaluation of the tobacco products to determine their storage status and organoleptic capacity and potential, as well as for the treatment of the ambient to lower AGE levels. For example, air or other samples may be taken and evaluated by a dosimeter or like device, to determine whether AGE levels exceed normal, after which measures could be implemented to remediate the ambient condition. All such methods and corresponding materials are contemplated and included.
摘要翻译：公开了用于测量晚期糖基化终产物（AGEs）的积累的方法，其基于这样的发现，即AGE存在于烟草及其副产物中。更具体地说，这些方法侧重于观察吸烟或以其他方式使用烟草的个体的AGE水平比非吸烟者增加。本方法涉及个体和烟草及其副产品，烟雾中AGE水平的测量。还公开了用于评估烟草产品以确定其储存状态和感官能力和潜力以及用于治疗环境以降低AGE水平的方法。例如，空气或其他样品可以通过剂量计或类似装置进行评估，以确定AGE水平是否超过正常，之后可以实施措施来修复环境条件。所有这些方法和相应的材料都被考虑并包括在内。

4. 发明授权

US5733933A Methods and materials for the diagnosis and treatment of conditions such as stroke 失效
公开(公告)号：US5733933A
公开(公告)日：1998-03-31
申请号：US473009
申请日：1995-06-07
申请人： Richard J. Bucala , Helen Vlassara , Anthony Cerami , Kevin J. Tracey
发明人： Richard J. Bucala , Helen Vlassara , Anthony Cerami , Kevin J. Tracey
IPC分类号： A61K31/155 , A61K38/17 , A61K39/00 , A61Q11/00 , C07K16/28 , G01N33/573 , G01N33/92
CPC分类号： G01N33/92 , A61K31/155 , A61K38/1709 , A61K39/0005 , C07K16/28 , G01N33/573 , A61K2039/6081 , G01N2333/922 , G01N2800/2871 , G01N2800/324
摘要： The in vivo oxidation of lipids and lipid-containing molecules has been discovered to be initiated by the concurrent reaction of such lipid materials with reducing sugars such as glucose, advanced glycosylation endproducts such as AGE-peptides, or a compound which forms advanced glycosylation endproducts, to form materials or particles known as AGE-lipids. AGE-lipids have been implicated in the aging process, the abnormal formation of lipofuscin and in various disease states such as diabetes, atherosclerosis, and stroke. Methods of treating stroke, and especially inhibiting the infarct size of stroke, using agents which inhibit the formation of AGE-lipids are disclosed. Additionally, a method of screening for neuroprotective agents which can be used to reduce the size and severity of the infarct size is disclosed.

5. 发明授权

US5610076A Method for detecting hemoglobin advanced glycosylation endproducts 失效
标题翻译：检测血红蛋白进展糖基化终产物的方法
公开(公告)号：US5610076A
公开(公告)日：1997-03-11
申请号：US236416
申请日：1994-04-29
申请人： Henry W. Founds , Michael A. Yamin , Richard J. Bucala , Anthony Cerami
发明人： Henry W. Founds , Michael A. Yamin , Richard J. Bucala , Anthony Cerami
IPC分类号： G01N33/53 , G01N33/531 , G01N33/72 , G01N33/543
CPC分类号： G01N33/723 , Y10S435/962 , Y10S435/975
摘要： The present invention relates to methods for the diagnosis and monitoring of diseases and disorders associate with advanced glycosylation endproducts (AGE) formation, such as diabetes and the ageing process. In particular, the invention is directed to detecting AGE-modified hemoglobin (Hb-AGE) for the foregoing purposes, and in improved assay therefore. The method involves diluting the sample in a dilution buffer, which dilution buffer comprises an anionic protein denaturing detergent at a concentration sufficient to denature hemoglobin-AGE without interfering in binding of reagents with hemoglobin-AGE the dilution buffer may also include a non-ionic surfactant at a concentration sufficient to facilitate detection of hemoglobin-AGE; and a denaturing agent at a concentration sufficient to denature hemoglobin-AGE and increase assay sensitivity, without denaturing binding of reagents to hemoglobin-AGE. After diluting the sample in the dilution buffer, the sample is contacted with means for detecting the presence of hemoglobin-AGE in the sample, and the presence of hemoglobin-AGE in the sample is detected with the detection means. Dilution buffers and kits for practicing the invention are also provided. In specific examples, the level of AGE in hemoglobin in samples from human and rat normal subjects and diabetic subjects is detected. The results obtained from human samples show a high degree of correlation between the level of hemoglobin-AGE in a sample and the level of hemoglobin-A.sub.1c in a sample. Most importantly, the invention is used to detect the "aminoguanidine effect," which is the decrease in the level of hemoglobin-AGE in a sample from a subject undergoing therapy with the AGE-inhibitor aminoguanidine.
摘要翻译：本发明涉及诊断和监测与晚期糖基化终产物（AGE）形成相关的疾病和病症的方法，例如糖尿病和衰老过程。特别地，本发明涉及为了上述目的检测AGE修饰的血红蛋白（Hb-AGE），并且因此改进了测定。该方法包括在稀释缓冲液中稀释样品，该稀释缓冲液包含浓度足以使血红蛋白-AGE变性的阴离子蛋白质变性洗涤剂，而不干扰试剂与血红蛋白-AGE的结合，稀释缓冲液还可以包括非离子表面活性剂浓度足以促进血红蛋白-AGE的检测; 和变性剂，其浓度足以使血红蛋白-AGE变性，并提高测定灵敏度，而不使试剂与血红蛋白-AGE结合变性。在稀释缓冲液中稀释样品后，将样品与用于检测样品中血红蛋白-AGE的存在的装置接触，并用检测装置检测样品中血红蛋白-AGE的存在。还提供了用于实施本发明的稀释缓冲液和试剂盒。在具体实例中，检测来自人和大鼠正常受试者和糖尿病受试者的样品中血红蛋白的AGE水平。从人体样品获得的结果显示样品中血红蛋白-AGE水平与样品中血红蛋白-Alc水平之间的高度相关性。最重要的是，本发明用于检测来自接受AGE抑制剂氨基胍治疗的受试者的样品中血红蛋白-AGE水平的“氨基胍效应”。

6. 发明授权

US5733524A Methods and materials for the diagnosis and treatment of conditions such as stroke 失效
标题翻译：用于诊断和治疗诸如中风的病症的方法和材料
公开(公告)号：US5733524A
公开(公告)日：1998-03-31
申请号：US479673
申请日：1995-06-07
申请人： Richard J. Bucala , Helen Vlassara , Anthony Cerami , Kevin J. Tracey
发明人： Richard J. Bucala , Helen Vlassara , Anthony Cerami , Kevin J. Tracey
IPC分类号： A61K31/155 , A61K38/17 , A61K39/00 , A61Q11/00 , C07K16/28 , G01N33/573 , G01N33/92 , A61K49/00 , G01N31/00 , G01N33/48
CPC分类号： A61K31/155 , A61K31/00 , A61K31/195 , A61K31/415 , A61K31/4178 , A61K31/70 , A61K38/1709 , A61K38/191 , A61K38/2006 , A61K38/217 , A61K38/38 , A61K39/0005 , A61K8/43 , A61Q19/08 , C07D405/14 , C07K16/28 , G01N33/533 , G01N33/573 , G01N33/68 , G01N33/6893 , G01N33/92 , A61K2039/6081 , G01N2333/922 , G01N2800/2871 , G01N2800/324
摘要： The in vivo oxidation of lipids and lipid-containing molecules has been discovered to be initiated by the concurrent reaction of such lipid materials with reducing sugars such as glucose, advanced glycosylation endproducts such as AGE-peptides, or a compound which forms advanced glycosylation endproducts, to form materials or particles known as AGE-lipids. AGE-lipids have been implicated in the aging process, the abnormal formation of lipofuscin and in various disease states such as diabetes, atherosclerosis, and stroke. Methods of treating stroke, and especially inhibiting the infarct size of stroke, using agents which inhibit the formation of AGE-lipids are disclosed. Additionally, a method of screening for neuroprotective agents which can be used to reduce the size and severity of the infarct size is disclosed.
摘要翻译：已经发现脂质和含脂质分子的体内氧化是通过这种脂质物质与还原糖如葡萄糖，高级糖基化终产物例如AGE-肽或形成晚期糖基化终产物的化合物的同时反应引发的，形成称为AGE-脂质的材料或颗粒。 AGE-脂质已经涉及老化过程，脂褐素的异常形成和各种疾病状态如糖尿病，动脉粥样硬化和中风。公开了使用抑制AGE-脂质形成的药物治疗中风的方法，特别是抑制中风的梗死面积。另外，公开了可用于减小梗死面积大小和严重程度的神经保护剂筛选方法。

7. 发明授权

US5869534A Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom 失效
标题翻译：脂质和含脂质颗粒的糖基化，以及从其衍生的诊断和治疗方法和材料
公开(公告)号：US5869534A
公开(公告)日：1999-02-09
申请号：US29417
申请日：1993-03-11
申请人： Richard J. Bucala , Helen Vlassara , Anthony Cerami
发明人： Richard J. Bucala , Helen Vlassara , Anthony Cerami
IPC分类号： G01N33/53 , A61K9/127 , A61K31/00 , A61K31/155 , A61K31/195 , A61K31/415 , A61K31/70 , A61K35/16 , A61K38/00 , A61K38/17 , A61K39/395 , A61K45/00 , A61P9/10 , A61P13/02 , A61P15/00 , A61P17/00 , A61P43/00 , G01N21/31 , G01N33/533 , G01N33/68 , G01N33/92
CPC分类号： G01N33/533 , A61K31/00 , A61K31/155 , A61K31/195 , A61K31/415 , A61K31/70 , A61K38/1709 , G01N33/6893 , G01N33/92 , G01N2800/042 , G01N2800/044 , G01N2800/323
摘要： The in vivo oxidation of lipids and lipid-containing molecules has been discovered to be initiated by the concurrent reaction of such lipid materials with reducing sugars such as glucose, advanced glycosylation endproducts such as AGE-peptides, or a compound which forms advanced glycosylation endproducts, to form materials or particles known as AGE-lipids. AGE-lipids have been implicated in the aging process, the abnormal formation of lipofuscin and in various disease states such as diabetes and atherosclerosis. Diagnostic methods are contemplated, extending in utility from the detection of the onset and course of conditions in which variations in lipid oxidation, AGE-lipid levels, LDL levels, apolipoprotein levels, apolipoprotein receptor binding the like, may be measured, to drug discovery assays. Corresponding methods of treatment and pharmaceutical compositions are disclosed that are based on an active ingredient or ingredients that demonstrates the ability to modulate the levels of all of the foregoing markers of lipid oxidation.
摘要翻译：已经发现脂质和含脂质分子的体内氧化是通过这种脂质物质与还原糖如葡萄糖，高级糖基化终产物例如AGE-肽或形成晚期糖基化终产物的化合物的同时反应引发的，形成称为AGE-脂质的材料或颗粒。 AGE-脂质已经涉及老化过程，脂褐素异常形成和各种疾病状态如糖尿病和动脉粥样硬化。考虑到诊断方法，从检测可以测量脂质氧化，AGE-脂质水平，LDL水平，载脂蛋白水平，结合载脂蛋白受体等的药物发现测定。公开了相应的治疗方法和药物组合物，其基于表现出调节脂质氧化的所有前述标记物的水平的能力的活性成分或成分。

8. 发明授权

US5700447A Methods and materials for the diagnosis and treatment of conditions such as stroke 失效
标题翻译：用于诊断和治疗诸如中风的病症的方法和材料
公开(公告)号：US5700447A
公开(公告)日：1997-12-23
申请号：US319747
申请日：1994-10-07
申请人： Richard J. Bucala , Helen Vlassara , Anthony Cerami , Kevin J. Tracey
发明人： Richard J. Bucala , Helen Vlassara , Anthony Cerami , Kevin J. Tracey
IPC分类号： A61K31/155 , A61K38/17 , G01N33/533 , G01N33/92 , G01N33/48
CPC分类号： A61K31/155 , A61K31/00 , A61K31/195 , A61K31/415 , A61K31/70 , A61K38/1709 , G01N33/533 , G01N33/6893 , G01N33/92 , G01N2800/042 , G01N2800/044 , G01N2800/323
摘要： The in vivo oxidation of lipids and lipid-containing molecules has been discovered to be initiated by the concurrent reaction of such lipid materials with reducing sugars such as glucose, advanced glycosylation endproducts such as AGE-peptides, or a compound which forms advanced glycosylation endproducts, to form materials or particles known as AGE-lipids. AGE-lipids have been implicated in the aging process, the abnormal formation of lipofuscin and in various disease states such as diabetes and atherosclerosis. Diagnostic methods are contemplated, extending in utility from the detection of the onset and course of conditions in which variations in lipid oxidation, AGE-lipid levels, LDL levels, apolipoprotein levels, apolipoprotein receptor binding the like, may be measured, to drug discovery assays. Corresponding methods of treatment and pharmaceutical compositions are disclosed that are based on an active ingredient or ingredients that demonstrates the ability to modulate the levels of all of the foregoing markers of lipid oxidation. A further aspect of the invention relates to the treatment of stroke and related maladies, and to agents and compositions that are prepared for such purpose.
摘要翻译：已经发现脂质和含脂质分子的体内氧化是通过这种脂质物质与还原糖如葡萄糖，高级糖基化终产物例如AGE-肽或形成晚期糖基化终产物的化合物的同时反应引发的，形成称为AGE-脂质的材料或颗粒。 AGE-脂质已经涉及老化过程，脂褐素异常形成和各种疾病状态如糖尿病和动脉粥样硬化。考虑到诊断方法，从检测可以测量脂质氧化，AGE-脂质水平，LDL水平，载脂蛋白水平，结合载脂蛋白受体等的药物发现测定。公开了相应的治疗方法和药物组合物，其基于表现出调节脂质氧化的所有前述标记物的水平的能力的活性成分或成分。本发明的另一方面涉及治疗中风和相关疾病，以及为此目的制备的药剂和组合物。

9. 发明授权

US06410598B1 Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis 失效
标题翻译：用于高级糖基化终末产物介导的淀粉样变性调节的组合物和方法
公开(公告)号：US06410598B1
公开(公告)日：2002-06-25
申请号：US08477364
申请日：1995-06-07
申请人： Michael P. Vitek , Anthony Cerami , Richard J. Bucala , Peter C. Ulrich , Helen Vlassara , Xini Zhang
发明人： Michael P. Vitek , Anthony Cerami , Richard J. Bucala , Peter C. Ulrich , Helen Vlassara , Xini Zhang
IPC分类号： A01N3752
CPC分类号： A61K31/15 , A61K31/155 , A61K31/195 , A61K31/415 , A61K31/425 , A61K31/655 , A61K38/00 , C07K14/4711 , C07K14/575
摘要： The present invention relates generally to the non-enzymatic glycosylation of amyloidogenic proteins and the consequent formation of advanced glycosylation endproducts (AGEs). It has been found that formation of AGE-amyloidogenic proteins can enhance amyloidosis. The invention further relates to compositions and methods for the prevention and treatment of amyloidosis associated with amyloid diseases, particularly neurodegenerative disease and Type II diabetes, and more particularly Alzheimer's disease. In a specific example, aggregation of an amyloidogenic peptide, &bgr;AP, is enhanced by the glycosylation reaction of &bgr;AP to form AGE-&bgr;AP as defined herein. Accordingly, the invention extends to a method for modulating the in vivo aggregation of amyloid polypeptides and associated amyloidosis by controlling the formation and presence of AGE-amyloid polypeptide. A corresponding diagnostic utility comprises the measurement of the course and extent of amyloidosis by a measurement of the presence and amount of AGEs and particularly, AGE-amyloid. An assay is included that may use the AGE-amyloid polypeptide of the present invention to identify disease states characterized by the presence of AGE-amyloid. Additionally, such an assay can be utilized to monitor therapy and thus adjust a dosage regimen for a given disease state characterized by the presence of AGE-amyloid.
摘要翻译：本发明一般涉及淀粉样蛋白形成蛋白的非酶糖基化，从而形成晚期糖基化终产物（AGEs）。已经发现AGE-淀粉样蛋白生成蛋白的形成可以增强淀粉样变性。本发明进一步涉及用于预防和治疗与淀粉样蛋白病，特别是神经变性疾病和II型糖尿病，更特别是阿尔茨海默病有关的淀粉样变性的组合物和方法。在具体实例中，通过βAP的糖基化反应来增强淀粉样蛋白原肽βAP的聚集，从而形成如本文所定义的AGE-βAP。因此，本发明延伸到通过控制AGE-淀粉样蛋白多肽的形成和存在来调节淀粉样蛋白多肽的体内聚集和相关淀粉样变性的方法。相应的诊断实用程序包括测量AGEs，特别是AGE-淀粉样蛋白的存在和量的淀粉样变性的过程和程度。包括可以使用本发明的AGE-淀粉样蛋白多肽来鉴定以AGE-淀粉样蛋白的存在为特征的疾病状态的测定。另外，这种测定可用于监测治疗，并因此调整特征在于AGE-淀粉样蛋白存在的给定疾病状态的剂量方案。

10. 发明授权

US5935927A Compositions and methods for stimulating amyloid removal in amyloidogenic diseases using advanced glycosylation endproducts 失效
标题翻译：使用高级糖基化终产物刺激淀粉样变性疾病中淀粉样蛋白去除的组合物和方法
公开(公告)号：US5935927A
公开(公告)日：1999-08-10
申请号：US501127
申请日：1996-08-10
申请人： Michael P. Vitek , Anthony Cerami , Richard J. Bucala , Peter C. Ulrich , Helen Vlassara , Xini Zhang
发明人： Michael P. Vitek , Anthony Cerami , Richard J. Bucala , Peter C. Ulrich , Helen Vlassara , Xini Zhang
IPC分类号： G01N33/68 , A61K31/047 , A61K31/15 , A61K31/155 , A61K31/195 , A61K31/415 , A61K31/425 , A61K31/428 , A61K31/655 , A61K31/7028 , A61K31/715 , A61K38/00 , A61K38/16 , A61K39/395 , A61K45/00 , A61P3/08 , A61P3/10 , A61P9/00 , A61P25/00 , A61P25/28 , A61P43/00 , C07D277/82 , C07D417/12 , C07H15/26 , C07K14/47 , C07K14/575 , A61K31/135 , A61K31/70
CPC分类号： A61K31/425 , A61K31/15 , A61K31/155 , A61K31/195 , A61K31/415 , A61K31/655 , C07K14/4711 , C07K14/575 , A61K38/00
摘要： The present invention relates generally to methods and compositions for treating amyloidogenic diseases such as Alzheimer's disease and the development of type II diabetes, in which deposition of amyloid in organs such as the brain and pancreas interfere with neurological function and insulin release, respectively. The methods and compositions are directed toward increasing the activity of scavenger cells within the body at recognizing and removing amyloid deposits from affected tissues and organs. Scavenger cells may be targeted to amyloid deposits by means of spontaneously-occurring chemical modifications called advanced glycosylation endproducts (AGEs). Compositions are described which increase scavenger cell activity towards AGE-modified amyloid. Amyloid removal may also be enhanced by increasing AGE levels in amyloid deposits within the body by administering AGE-modified amyloid targeting agents, which after becoming situated at sites containing amyloid, subsequently attract scavenger cells to degrade attendant amyloid. These methods and associated compositions result in a decrease in the extent of amyloid deposits in tissues, reducing the attendant pathology.
摘要翻译： PCT No.PCT / US95 / 01380 Sec。 371日期：1996年8月10日 102（e）日期1996年8月10日PCT提交1995年2月2日PCT公布。第WO95 / 20979号公报日期：1995年8月10日本发明一般涉及用于治疗淀粉样变性疾病如阿尔茨海默氏病和II型糖尿病发展的方法和组合物，其中淀粉样蛋白沉积在诸如脑和胰腺的器官中干扰神经功能和胰岛素释放，分别。所述方法和组合物旨在增加识别和去除受影响组织和器官中的淀粉样蛋白沉积物中体内清除细胞的活性。清除细胞可以通过称为晚期糖基化终产物（AGE）的自发发生的化学修饰来靶向淀粉样蛋白沉积物。描述了增加AGE修饰的淀粉样蛋白的清除细胞活性的组合物。通过施用AGE修饰的淀粉样蛋白靶向剂，其在位于含有淀粉样蛋白的位点后，随后吸引清道细胞降解伴随的淀粉样蛋白，也可以通过增加体内淀粉样蛋白沉积物中的AGE水平来增强淀粉样蛋白的去除。这些方法和相关组合物导致组织中淀粉样蛋白沉积的程度降低，减少伴随的病理。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式